Compare Kinross Gold Corporation (KGC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Revvity Inc — how do they compare? Kinross Gold Corporation trades at $24.29 (market cap $28.07B), while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Kinross Gold Corporation is far larger — about 2.3× Revvity Inc's market cap, and Kinross Gold Corporation pays the higher dividend (0.62%). Which is the better fit depends on your goals.
| KGC | RVTY | |
|---|---|---|
Market Cap | $28.07B | $12.33B |
Sector | Basic Materials | Technology |
52-Week High | $38.06 | $117.75 |
52-Week Low | $15.42 | $82.26 |
Enterprise Value | $26.62B | $14.82B |
Dividend Yield | 0.62% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $23.43, up 3.79% on the day, with strong fundamentals including a P/E of 9.59 and robust profitability metrics. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 results due July 29, 2026. Technical indicators show bearish momentum despite oversold RSI conditions, while analyst consensus remains strongly bullish with a $37.20 price target representing 59% upside potential.
KGC presents a compelling value opportunity with attractive valuation multiples and strong cash flow generation. Key risks include gold price volatility and rising operational costs. The stock's current discount to analyst targets and improving financial trajectory suggest potential for significant appreciation, though investors should monitor Q2 earnings and gold market dynamics closely.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
